Loading
Latest filing published 03 Jun 2022 for INVO Bioscience, Inc., €158k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Kevin Doody (senior executive) discloses dealings in INVO Fertility, Inc. to SEC (Form 4). Between 31 December 2020 and 1 June 2022, the trades on record add up to 3 filings.
No open-market sale appears; the market trades are 1 purchase worth €158k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 2 share grants. 2022 to date brings 1 purchase and no sales.
The newest entry dates from 3 June 2022: an open-market purchase of €158k, in INVO Fertility, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations